June 16

0 comments

Endo Pharmaceuticals Should Survive Up To $3 Billion Worth Of Opioid Litigation, Making Shares Undervalued – Seeking Alpha

By 

June 16, 2019


Endo Pharmaceuticals Should Survive Up To $3 Billion Worth Of Opioid Litigation, Making Shares Undervalued  Seeking Alpha

Endo is a well managed, organic R&D company returning to growth despite looming litigation risks on the horizon. Its branded drugs and sterile injectable portfo.

Read more: seekingalpha.com

About the author

You might also like

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Direct Your Visitors to a Clear Action at the Bottom of the Page